Serum levels of soluble syndecan-1 in Hodgkin's lymphoma

Anticancer Research

Volumn 25, Issue 6 C, 2005, Pages 4743-4746

  Vassilakopoulos, Theodoros P ^a   Kyrtsonis, Marie Christine ^a   Papadogiannis, Argiroula ^a   Nadali, Gianpaolo ^b   Angelopoulou, Maria K ^a   Tzenou, Tatiana ^a   Dimopoulou, Maria N ^a   Siakantaris, Marina P ^a   Kontopidou, Flora N ^a   Kalpadakis, Christina ^a   Kokoris, Styliani I ^a   Dimitriadou, Evangelia M ^a   Tsaftaridis, Panayiotis ^a   Pizzolo, Giovanni ^b   Pangalis, Gerassimos A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Hodgkin's; Lymphoma; Serum levels; Syndecan 1

Indexed keywords

CD30 ANTIGEN; INTERLEUKIN 10; SYNDECAN 1;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL INTERACTION; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROENVIRONMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REED STERNBERG CELL;

ADOLESCENT; ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PROTEOGLYCANS; SYNDECAN-1; SYNDECANS;

EID: 28444475477     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Kanzler H, Küppers R, Hansmann ML and Rajewsky K: Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 184: 1495-1505, 1996.
2. Carbone A, Gloghini A, Gaidano G et al: Expression status of BCL-6 and syndecan-1 indentifies distinct histogenetic subtypes of Hodgkin's disease. Blood 92: 2220-2228, 1998.
3. Carbone A, Gloghini A, Gattei V et al: Reed-Sternberg cells of classical Hodgkin's disease react with the plasma cell-specific monoclonal antibody B-B4 and express human syndecan-1. Blood 89: 3787-3794, 1997.
4. Seidel C, Sundan A, Hjorth M et al: Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 95: 388-392, 2000.
5. Kyrtsonis MC, Vassilakopoulos TP, Siakantaris MP et al: Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. Eur J Haematol 72: 252-258, 2004.
6. Dhodapkar MV, Abe E, Theus A et al: Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth and bone differentiation. Blood 91: 2679-2688, 1998.
7. Vassilakopoulos TP and Pangalis GA: Biological prognostic factors in Hodgkin's lymphoma. Haema 7: 147-164, 2004.
8. Vassilakopoulos TP, Nadali G, Angelopoulou MK et al: The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma. Haematologica 87: 701-708, 2002.
9. Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP et al: Combination chemotherapy plus low dose involved field radiation for early clinical stage Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 59: 765-781, 2004.
10. Nadali G, Tavecchia L, Zanolin E et al: Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood 91: 3011-3016, 1998.
11. Sarris AH, Kliche KO, Pethambaram P et al: Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol 10: 433-440, 1999.
12. Vassilakopoulos TP, Nadali G, Angelopoulou MK et al: Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma. Haematologica 86: 274-281, 2001.
13. Armitage P and Berry G: Statistical Methods in Medical Research. 2nd ed. Oxford: Blackwell Scientific Publications, 1987.
14. Kaplan E and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 55: 457-481, 1958.
15. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1966.
16. Hasenclever D and Diehl V: A prognostic score for advanced Hodgkin's disease. N Engl J Med 339: 1506-1514, 1998.